Clinical Trials List
Protocol NumberR092670SCH3005
2009-12-01 - 2013-12-31
Phase III
Terminated3
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater-Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmitate to Treatment as Usual With Oral Antipsychotic Monotherapy in Adults With Schizophrenia
-
Trial Applicant
Johnson & Johnson
-
Sponsor
Johnson & Johnson
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- 黃介良 Division of Psychiatry
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 劉英杰 Division of Psychiatry
The Actual Total Number of Participants Enrolled
0 Completed
Co-Principal Investigator
- Kuan-Yi Wu Division of Psychiatry
The Actual Total Number of Participants Enrolled
0 Completed
Condition/Disease
Schizophenia
Objectives
To compare long-acting injectable Paliperidone Palmitate to treatment as usual with oral antipsychotic monotherapy in adults with schizophrenia
Test Drug
INVEGA SUSTENNA
Active Ingredient
Paliperidone Palmitete
Dosage Form
Injection
Dosage
25mg, 50mg, 75mg, 100mg, 150mg
Endpoints
PANSS, PSP, CGI-S, CGI-C, EQ5D, SWN, TSQM
Inclution Criteria
Adults with schizophrenia
Exclusion Criteria
None
The Estimated Number of Participants
-
Taiwan
30 participants
-
Global
766 participants
